Technical Analysis for ONC - Oncimmune Holdings Plc

Grade Last Price % Change Price Change
C 220.0 -7.37% -17.50
ONC closed down 7.37 percent on Tuesday, May 11, 2021, on 37 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical ONC trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Doji - Bearish? Reversal -7.37%
20 DMA Support Bullish -6.78%
180 Bullish Setup Bullish Swing Setup -6.78%
MACD Bearish Signal Line Cross Bearish -5.58%
Narrow Range Bar Range Contraction -5.58%
NR7 Range Contraction -5.58%
Inside Day Range Contraction -5.58%
20 DMA Support Bullish -6.78%
20 DMA Support Bullish -7.56%
Older End-of-Day Signals for ONC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oncimmune Holdings Plc Description

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Health Medicine Earl Cancer Oncology Clinical Medicine Blood Rtt Antibody Biomarker Tumor Biomarkers Platform Technology The National Cancers Nhs Lung Cancer National Health Service

Is ONC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 261.625
52 Week Low 81.0
Average Volume 169,786
200-Day Moving Average 176.93
50-Day Moving Average 213.82
20-Day Moving Average 230.20
10-Day Moving Average 235.45
Average True Range 13.56
ADX 15.76
+DI 22.70
-DI 27.30
Chandelier Exit (Long, 3 ATRs ) 220.95
Chandelier Exit (Short, 3 ATRs ) 240.67
Upper Bollinger Band 251.25
Lower Bollinger Band 209.15
Percent B (%b) 0.26
BandWidth 18.29
MACD Line 5.64
MACD Signal Line 7.19
MACD Histogram -1.5483
Fundamentals Value
Market Cap 139.79 Million
Num Shares 63.5 Million
EPS -12.30
Price-to-Earnings (P/E) Ratio -17.89
Price-to-Sales 202.09
Price-to-Book 49.27
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 248.79
Resistance 3 (R3) 251.34 244.31 243.99
Resistance 2 (R2) 244.31 236.98 243.03 242.39
Resistance 1 (R1) 232.15 232.45 228.64 229.60 240.79
Pivot Point 225.12 225.12 223.36 223.84 225.12
Support 1 (S1) 212.96 217.79 209.44 210.40 199.21
Support 2 (S2) 205.93 213.26 204.65 197.61
Support 3 (S3) 193.77 205.93 196.01
Support 4 (S4) 191.21